fbpx

HGCO19: India’s first indigenous mRNA vaccine candidate receives approval

  • IASbaba
  • December 14, 2020
  • 0
UPSC Articles
Print Friendly, PDF & Email

HGCO19: India’s first indigenous mRNA vaccine candidate receives approval

Part of: GS Prelims and GS-II –Health & GS-III – Sci & Tech

In news

  • India’s first indigenous mRNA vaccine candidate, HGCO19, has received approval from Indian Drug regulators to initiate Phase one and two human clinical trials.

Key takeaways

  • HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology.
  • The mRNA vaccines do not use the conventional model to produce immune response.
  • Instead, they carry the molecular instructions to make the protein in the body through a synthetic RNA of the virus.
  • mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline.
  • The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms.

For a dedicated peer group, Motivation & Quick updates, Join our official telegram channel – https://t.me/IASbabaOfficialAccount

Search now.....